Endo Pharmaceuticals has entered into a licensing agreementwith Novartis to obtain the exclusive US marketing rights for Voltaren Gel(diclofenac sodium topical gel) 1%. Endo said it expects to commercializeVoltaren Gel using one of its two specialty sales forces, consisting of 160reps, prior to executing a full physician launch in late May with an additional275 contract sales reps targeting primary care physicians who prescribe bothNSAIDs and Cox-2s.
Voltaren Gel received FDAapproval in October 2007. Endo estimates US peak annual sales for Voltaren Gelas an osteoarthritis pain treatment in the range of $250-300 million.
From the April 01, 2008 Issue of MM+M - Medical Marketing and Media
